PEER-REVIEWED ARTICLES AND REVIEWS
Wildschut M, Mena J, Dördelmann C, van Oostrum M, Hale B, Settelmeier J, Festl Y, Lysenko V, Schürch P, Ring A, Severin Y, Bader M, Pedrioli P, Goetze S, van Drogen A, Balabanov S, Skoda R, Lopes M, Wollscheid B*, Theocharides A*, Snijder B*
*Senior authors
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis
Nat Commu. 2023 Oct 12;14(1):6414. doi: 10.1038/s41467-023-42101-z.
Maru B, Messikommer A, Huang L, Seipel K, Kovecses O, Valk PJM, Theocharides A, Mercier FE, Pabst T, McKeague M, Luedtke NW.
PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy
Cell Rep Med. 2023 Sep 19;4(9):101191. doi: 10.1016/j.xcrm.2023.101191. Epub 2023 Sep 7.
Grockowiak E, Korn C, Rak J, Lysenko V, Hallou A, Panvini FM, Williams M, Fielding C, Fang Z, Khatib-Massalha E, García-García A, Li J, Khorshed RA, González-Antón S, Baxter EJ, Kusumbe A, Wilkins BS, Green A, Simons BD, Harrison CN, Green AR, Lo Celso C, Theocharides A, Méndez-Ferrer S.
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms
Nat Cancer. 2023 Aug;4(8):1193-1209. doi: 10.1038/s43018-023-00607-x. Epub 2023 Aug 7.
Marques-Maggio E, Maccio U, Marx A, Galli S, Schwab N, Frank A, Hamelin B, Varga Z, Nombela-Arrieta C, Mertz KD, Theocharides A*, Koelzer VH*
*Senior authors
Bone marrow haematopoiesis in patients with COVID-19
Histopathology. 2023 Oct;83(4):582-590. doi: 10.1111/his.14969. Epub 2023 Jun 14.
Lysenko V, Schürch PM, Tuzlak S, van Wijk NW, Kovtonyuk LV, Becher B, Manz MG, Kreutmair S, Theocharides APA.
Leukemia. 2023 Apr 24. doi: 10.1038/s41375-023-01903-2. Online ahead of print.
Calreticulin mutations affect its chaperone function and perturb the glycoproteome.
Schürch PM, Malinovska L, Hleihil M, Losa M, Hofstetter MC, Wildschut MHE, Lysenko V, Lakkaraju AKK, Maat CA, Benke D, Aguzzi A, Wollscheid B, Picotti P, Theocharides APA.
Cell Rep. 2022 Nov 22;41(8):111689. doi: 10.1016/j.celrep.2022.111689.
CALR loss-of-heterozygosity as a potential driver for extramedullary AML.
Weller MC, Haralambieva E, Bühler MM, Benz R, Theocharides APA, Balabanov S.
Ann Hematol. 2022 Nov;101(11):2571-2573. doi: 10.1007/s00277-022-04976-8. Epub 2022 Sep 26.
Production and Characterization of Peptide Antibodies to the C-Terminal of Frameshifted Calreticulin Associated with Myeloproliferative Diseases.
Mughal FP, Bergmann AC, Huynh HUB, Jørgensen SH, Mansha I, Kesmez M, Schürch PM, Theocharides APA, Hansen PR, Friis T, Holmström MO, Ciplys E, Slibinskas R, Højrup P, Houen G, Trier NH.
Int J Mol Sci. 2022 Jun 18;23(12):6803. doi: 10.3390/ijms23126803.
Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients.
Wagner U, Wong C, Camenisch U, Zimmermann K, Rechsteiner M, Valtcheva N, Theocharides A, Widmer CC, Manz MG, Moch H, Wild PJ, Balabanov S
J Mol Diagn. 2022 Jun 16:S1525-1578(22)00159-3. doi: 10.1016/j.jmoldx.2022.05.003. Online ahead of print.
Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia.
Krieg S, Seeger H, Hofmann P, Del Prete C, Manz MG, Müller AM, Theocharides A
Br J Haematol. 2022 Feb;196(3):781-784. doi: 10.1111/bjh.17854. Epub 2021 Oct 5.
Tan G, Wolski WE, Kummer S, Hofstetter MC, Theocharides APA, Manz MG, Aebersold R, Meier-Abt F.
Blood Adv. 2022 Jan 10:bloodadvances.2021005344. doi: 10.1182/bloodadvances.2021005344. Online ahead of print.
Saito Y, Willinger T, Theocharides APA.
Front Immunol. 2021 Dec 23;12:829644. doi: 10.3389/fimmu.2021.829644. eCollection 2021.
CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes.
Olschok K, Han L, de Toledo MAS, Böhnke J, Graßhoff M, Costa IG, Theocharides A, Maurer A, Schüler HM, Buhl EM, Pannen K, Baumeister J, Kalmer M, Gupta S, Boor P, Gezer D, Brümmendorf TH, Zenke M, Chatain N, Koschmieder S.
Stem Cell Reports. 2021 Nov 9;16(11):2768-2783. doi: 10.1016/j.stemcr.2021.09.019. Epub 2021 Oct 21.
Krieg S, Seeger H, Hofmann P, Del Prete C, Manz MG, Müller AM, Theocharides APA.
Br J Haematol. 2022 Feb;196(3):781-784. doi: 10.1111/bjh.17854. Epub 2021 Oct 5.
An integrated genomic approach to dissect the genetic landscape regulating the cell-to-cell transfer of α-synuclein.
Kara E, Crimi A, Wiedmer A, Emmenegger M, Manzoni C, Bandres-Ciga S, D'Sa K, Reynolds RH, Botía JA, Losa M, Lysenko V, Carta M, Heinzer D, Avar M, Chincisan A, Blauwendraat C, García-Ruiz S, Pease D, Mottier L, Carrella A, Beck-Schneider D, Magalhães AD, Aemisegger C, Theocharides A, Fan Z, Marks JD, Hopp SC, Abramov AY, Lewis PA, Ryten M, Hardy J, Hyman BT, Aguzzi A.
Cell Rep. 2021. Jun 8;35(10):109189. doi: 10.1016/j.celrep.2021.109189.
Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria.
Halloy F, Iyer PS, Ghidini A, Lysenko V, Barman-Aksözen J, Grubenmann CP, Jucker J, Wildner-Verhey van Wijk N, Ruepp MD, Minder EI, Minder AE, Schneider-Yin X, Theocharides A, Schümperli D, Hall J
Cell Chem Biol. 2021 Mar 13:S2451-9456(21)00106-9. doi: 10.1016/j.chembiol.2021.02.021. Online ahead of print.
Disruption of CSF-1R signaling inhibits growth of AML with inv(16).
Simonis A, Russkamp NF, Mueller J, Wilk CM, Wildschut MHE, Myburgh R, Wildner-Verhey van Wijk N, Mueller R, Balabanov S, Valk PJM, Theocharides A, Manz MG
Blood Adv. 2021 Mar 9;5(5):1273-1277. doi: 10.1182/bloodadvances.2020003125.
Meier-Abt F, Wolski WE, Tan G, Kummer S, Amon S, Manz MG, Aebersold R, Theocharides A
Reduced CXCL4/PF4 expression as a driver of increased human hematopoietic stem and progenitor cell proliferation in polycythemia vera.
Blood Cancer J. 2021 Feb 11;11(2):31. doi: 10.1038/s41408-021-00423-5.
Rütsche CV, Haralambieva E, Lysenko V, Balabanov S, Theocharides A
A patient with a germline GATA2 mutation and primary myelofibrosis.
Blood Adv. 2021 Feb 9;5(3):791-795. doi: 10.1182/bloodadvances.2020003401.
Irmisch A, Bonilla X, Chevrier S…Theocharides A… Levesque M
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support Cancer Cell. 2021 Jan 20:S1535-6108(21)00048-9. doi: 10.1016/j.ccell.2021.01.004. Online ahead of print.
Lysenko V, Wildner-Verhey van Wijk N, Zimmermann K, Weller M, Bühler M, Wildschut MHE, Schürch P, Fritz C, Wagner U, Calabresi L, Psaila B, Flavell RA, Vannucchi AM, Mead AJ, Wild PJ, Dirnhofer S, Manz MG, Theocharides APA
Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice
Blood Adv. 2020 Jun 9;4(11):2477-2488. doi: 10.1182/bloodadvances.2019001364.
Delivery of oligonucleotides to bone marrow to modulate ferrochelatase splicing in a mouse model of erythropoietic protoporphyria.
Halloy F, Iyer PS, Ćwiek P, Ghidini A, Barman-Aksözen J, Wildner-Verhey van Wijk N, Theocharides APA, Minder EI, Schneider-Yin X, Schümperli D, Hall J.
Nucleic Acids Res. 2020 May 21;48(9):4658-4671. doi: 10.1093/nar/gkaa229.
Stelling A, Wu CT, Bertram K, Hashwah H, Theocharides APA, Manz MG, Tzankov A, Müller A
Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.
Blood Adv. 2019 Oct 22;3(20):3020-3032. doi: 10.1182/bloodadvances.2019000210.
Hashwah H, Bertram K, Stirm K, Stelling A, Wu CT, Kasser S, Manz MG, Theocharides AP, Tzankov A, Müller A
The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma.
EMBO Mol Med. 2019 Oct;11(10):e10576. doi: 10.15252/emmm.201910576. Epub 2019 Sep 12.
Amon S, Meier-Abt F, Gillet LC, Dimitrieva S, Theocharides A, Manz MG, Aebersold R
Sensitive quantitative proteomics of human hematopoietic stem and progenitor cells by data independent acquisition mass spectrometry.
Mol Cell Proteomics. American Society for Biochemistry and Molecular Biology; 2019 Apr 11; mcp.TIR119.001431.
Drexler B, Passweg JR, Tzankov A, Bigler M, Theocharides A, Cantoni N, Keller P, Stussi G, Ruefer A, Benz R, Favre G, Lundberg P, Nienhold R, Fuhrer A, Biaggi C, Manz MG, Bargetzi M, Mendez-Ferrer S, Skoda RC; Swiss Group for Clinical Cancer Research (SAKK).
The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14.
Haematologica. 2019 Apr;104(4):710-716. doi: 10.3324/haematol.2018.200014. Epub 2018 Nov 8.
Theocharides A, Manz MG
Finally: development of humanized lymph nodes.
Nat Methods. 2018 Aug;15(8):580-582
Guiducci E, Lemberg C, Küng N, Schraner E, Theocharides A, LeibundGut-Landmann S
Candida albicans-Induced NETosis Is Independent of Peptidylarginine Deiminase 4.
Front Immunol. 2018 Jul 9;9:1573. doi: 10.3389/fimmu.2018.01573. eCollection 2018.
Widmer C, Balabanov S, Schanz U, Theocharides A
Transient paraproteinemia after allogeneic hematopoietic stem cell transplantation is an underexplored phenomenon associated with graft versus host disease
Oncotarget. 2017 Nov 15;8(63):106333-106341. doi: 10.18632/oncotarget.22462. eCollection 2017 Dec 5.
Lysenko V, McHugh D, Behrmann L, Rochat M, Wilk C, Kovtonyuk L, Bourquin JP, Münz C, Manz MG, Speck R, Theocharides A
Humanised mouse models for haematopoiesis and infectious diseases
Swiss Med Wkly. 2017;147:w14516
Ellegast JM, Rauch PJ, Kovtonyuk LV, Müller R, Wagner, U, Saito Y, Wildner-Verhey van Wijk N, Fritz C, Rafiei A, Lysenko V, Dudkiewicz E, Theocharides A, Soldini D, Goede JS, Flavell RA, Manz MG
INV(16) and NPM1MUT AML engraft human cytokine knock-in mice
Blood 2016 :blood-2015-12-689356; doi:10.1182/blood-2015-12-689356
Theocharides A, Lundberg P, Lakkaraju A, Lysenko V, Myburgh V, Aguzzi A, Skoda R, Manz M
Homozygous Calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency
Blood. 2016 Jun 23;127(25):3253-9. doi: 10.1182/blood-2016-02-696310. Epub 2016 Mar 24.
Theocharides A, Rongvaux A, Fritsch K, Flavell RA, Manz MG.
Humanized hemato-lymphoid system mice.
Haematologica. 2016 Jan;101(1):5-19. doi: 10.3324/haematol.2014.115212.
Mager LF, Riether C, Schürch CM, Banz Y, Wasmer MH, Stuber R, Theocharides A,
Li X, Xia Y, Saito H, Nakae S, Baerlocher GM, Manz MG, McCoy KD, Macpherson AJ,
Ochsenbein AF, Beutler B, Krebs P.
IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.
J Clin Invest. 2015 Jul 1;125(7):2579-91. Epub 2015 May 26.
Theocharides A, Dobson S, Laurenti E, Notta F, Voisin V, Cheng P, Yuan J, Guidos CJ, Minden M, Mullighan C,
Torlakovic E, Dick JE.
Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts
Leukemia. 2015 Jan;29(1):177-87. Epub 2014 May 5.
Theocharides A, Jin L, Cheng P, Malko A, Prasolava T, Minden M, Danska J, Dick JE, Wang JC.
Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.
J Exp Med. 2012 Sep 24;209(10):1883-99. Epub 2012 Sep 3.
Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, Dirnhofer S, Tichelli A, Tzankov A.
Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Br J Haematol. 2009 Jul;146(2):150-7. Epub 2009 May 19.
Theocharides A, Passweg JR, Medinger M, Looser R, Li S, Hao-Shen H, Buser AS, Gratwohl A, Tichelli A, Skoda RC.
Haematologica. 2008 Dec;93(12):1890-3. Epub 2008 Sep 11.
Tzankov A, Sotlar K, Muhlematter D, Theocharides A, Went P, Jotterand M, Horny HP, Dirnhofer S.
J Clin Pathol. 2008 Aug;61(8):958-61.
Patient and product factors affecting platelet transfusion results
Transfusion. 2008 Apr;48(4):681-7. Epub 2008 Jan 15.
Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda RC.
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations
Blood. 2008 Apr 1;111(7):3863-6. Epub 2008 Jan 14.
Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, Ferrari M, Gisslinger H, Kralovics R, Cremonesi L, Skoda R, Cazzola M.
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
Blood. 2008 Feb 1;111(3):1686-9. Epub 2007 Nov 5.
Recher M, Lang KS, Navarini A, Hunziker L, Lang PA, Fink K, Freigang S, Georgiev P, Hangartner L, Zellweger R, Bergthaler A, Hegazy AN, Eschli B, Theocharides A, Jeker LT, Merkler D, Odermatt B, Hersberger M, Hengartner H, Zinkernagel RM.
Extralymphatic virus sanctuaries as a consequence of potent T-cell activation
Nat Med. 2007 Nov;13(11):1316-23. Epub 2007 Nov 4.
Theocharides A, Boissinot M, Girodon F, Garand R, Teo S-S, Lippert E, Tichelli A,
Hermouet S, Skoda RC.
Leukemic blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Blood. 2007 Jul 1;110(1):375-9. Epub 2007 Mar 15.
Kralovics R, Teo S-S, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC.
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset
of patients with myeloproliferative disorders 2)
Blood. 2006 Aug 15;108(4):1377-80. Epub 2006 May 4.
Recher M, Lang KS, Hunziker L, Freigang S, Eschli B, Harris NL, Navarini A, Senn BM
Fink K, Lotscher M, Hangartner L, Zellweger R, Hersberger M, Theocharides A,
Hengartner H, Zinkernagel RM.
Deliberate Removal of T cell help improves virus-neutralizing antibody production
Nat Immunol. 2004 Sep;5(9):934-42. Epub 2004 Aug 8.
